Clinical Trial

Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study will enroll patients with prior IO therapy (alone or in combination with chemotherapy or in combination with other IO agents) regardless of the PD-L1 level, into a non-randomized combination trial, with primary endpoint of disease control rate.
Protocol Amendment History 1 change
notable Primary completion pushed: 2026-04 -> 2026-12 2026-05-23
Trial Details
NCT Number NCT03527108
Lead Sponsor Fox Chase Cancer Center
Collaborators: Bristol-Myers Squibb, Eli Lilly and Company
Conditions Non Small Cell Lung Cancer
Enrollment 36 participants
Start Date 2020-10-08
Primary Completion 2026-12 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-05-22